49Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Colombia
Neuroscience Intelligence
Colombia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #42 of 50 · Data maturity A · Research score 29.1 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
14Recruiting trials
20Publications
21Institutions
Executive interpretation
Colombia ranks #42 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC128 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.50 recruiting
Washington University School of Medicine33 recruiting
Sumitomo Pharma America, Inc.30 recruiting
Boehringer Ingelheim20 recruiting
Forest Laboratories20 recruiting
Pfizer20 recruiting
Hoffmann-La Roche20 recruiting
Novartis Pharmaceuticals21 recruiting
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul10 recruiting
Disease activity
Parkinsons13trials
Schizophrenia6trials
Other Neurology5trials
Pain Neuropathy4trials
Epilepsy4trials
Stroke3trials
Alzheimers3trials
Depression3trials
Multiple Sclerosis2trials
Autism2trials
Research institutions
Pontificia Universidad JaverianaOpenAlexlinked institution
Universidad de la CostaOpenAlexlinked institution
Hospital Universitario San IgnacioOpenAlexlinked institution
Meditech FoundationOpenAlexlinked institution
Universidad De SantanderOpenAlexlinked institution
International Center for Tropical AgricultureOpenAlexlinked institution
Universidad de CaldasOpenAlexlinked institution
Universidad Colegio Mayor de CundinamarcaOpenAlexlinked institution
Universidad Santo TomásOpenAlexlinked institution
Institución Universitaria Visión de las AméricasOpenAlexlinked institution
Clinical evidence trail
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06895005Transcutaneous Auricular Vagus Nerve Stimulation in Patients With StrokeNOT_YET_RECRUITING
NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)ACTIVE_NOT_RECRUITING
NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDPalliative Care Needs in Patients With Early-Onset Alzheimer's Disease: A Cross-Sectional Report.2026-12-01
PUBMEDAptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.2026-12-01
PUBMEDA longitudinal examination of gut microbiota dysbiosis and neuro-behavioral phenotypes of poly(I:C)-maternal immune activation in a preclinical model of autism and schizophrenia.2026-11-01
PUBMEDComparison of recommendations for initial adult traumatic brain injury management across clinical practice guidelines and consensus statements: a scoping review.2026-11-01
PUBMEDHemolytic brain edema: a new pathophysiologic approach for diagnosis and management of neurotrauma patients.2026-10-15
PUBMEDContrasting clinical trajectories in two ALS patients with rare FUS variants: implications for variant interpretation, penetrance, and trial readiness.2026-10-08
PUBMEDExplosive Weapons Trauma Care Collective (EXTRACCT) Blast Injury Clinical Practice Guideline: Traumatic Brain Injury From Blast and Penetrating Mechanisms in Settings With Variable Resource Availability.2026-10-01
PUBMEDUnlocking global neurosurgery: how telemedicine addresses unmet needs and future prospects - a scoping review.2026-10-01
PUBMEDReduced FOXP3 expression and its association with genetic ancestry in neuromyelitis Optica spectrum disorder: a Colombian cohort.2026-10-01
PUBMEDChanges in EEG-derived entropy are associated with symptom improvement in major depressive disorder following electroconvulsive therapy.2026-10-01
PUBMEDNeuromonitoring in the Decompressed Brain: Rethinking Physiology, Monitoring, and Thresholds After Decompressive Craniectomy.2026-09-24
PUBMEDFXTAS and the Spectrum of FMR1 Premutation-Associated Phenotypes in Latin America: A Scoping Review.2026-09-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.